Top

10-08-2018 | Rheumatoid arthritis | Article

Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adolopment of the 2015 American College of Rheumatology guidelines

Journal: Clinical Rheumatology

Authors: Thurayya Arayssi, Manale Harfouche, Andrea Darzi, Samar Al Emadi, Khalid A. Alnaqbi, Humeira Badsha, Farida Al Balushi, Carole Dib, Bassel Elzorkany, Hussein Halabi, Mohammed Hammoudeh, Wissam Hazer, Basel Masri, Mira Merashli, Mohammed Omair, Nelly Salloum, Imad Uthman, Sumeja Zahirovic, Nelly Ziade, Raveendhara R. Bannuru, Timothy McAlindon, Mohamed A. Nomier, Jasvinder A. Singh, Robin Christensen, Peter Tugwell, Holger Schünemann, Elie A. Akl

Publisher: Springer London

Abstract

Clinical practice guidelines can assist rheumatologists in the proper prescription of newer treatment for rheumatoid arthritis (RA). The objective of this paper is to report on the recommendations for the management of patients with RA in the Eastern Mediterranean region. We adapted the 2015 American College of Rheumatology guidelines in two separate waves. We used the adolopment methodology, and followed the 18 steps of the “Guidelines 2.0” comprehensive checklist for guideline development. For each question, we updated the original guidelines’ evidence synthesis, and we developed an Evidence Profile (EP) and an Evidence to Decision (EtD) table. In the first wave, we adoloped eight out of the 15 original questions on early RA. The strength changed for five of these recommendations from strong to conditional, due to one or more of the following factors: cost, impact on health equities, the balance of benefits, and harms and acceptability. In the second wave, we adoloped eight out of the original 44 questions on established RA. The strength changed for two of these recommendations from strong to conditional, in both cases due to cost, impact on health equities, balance of benefits and harms, and acceptability. The panel also developed a good practice recommendation. We successfully adoloped 16 recommendations for the management of early and established RA in the Eastern Mediterranean region. The process proved feasible and sensitive to contextual factors.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRef

Chatzidionysiou K, Emamikia S, Nam JL, Ramiro S, Smolen J, Van Der Heijde D, Dougados M, Bijlsma JWJ, Burmester G, Scholte-Voshaar M, Van Vollenhoven R, Landewe R (2016) Efficacy and safety of conventional and targeted synthetic disease-modifying antirheumatic drugs as well as glucocorticoids: a systematic literature review informing the 2016 update of the eular recommendations for the management of rheumatoid arthritis. In: Arthritis and rheumatology. Wiley, Hoboken

Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423(6937):356–361CrossRef

Pincus T (1995) Long-term outcomes in rheumatoid arthritis. Rheumatology 34(suppl 2):59–73CrossRef

Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1316–1322CrossRef

Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC (2003) Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 48(4):917–926CrossRef

Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370(9602):1861–1874CrossRef

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis: Annrheumdis 2013:204573

Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R (2014) Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73(1):3–5CrossRef

10.

Darzi A, Harfouche M, Arayssi T, Alemadi S, Alnaqbi KA, Badsha H, Al Balushi F, Elzorkany B, Halabi H, Hamoudeh M, Hazer W, Masri B, Omair MA, Uthman I, Ziade N, Singh JA, Christiansen R, Tugwell P, Schunemann HJ, Akl EA (2017) Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. Health Qual Life Outcomes 15(1):183. https://doi.org/10.1186/s12955-017-0754-1 CrossRefPubMedPubMedCentral

11.

Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, Brignardello-Petersen R, Neumann I, Falavigna M, Alhazzani W, Santesso N, Zhang Y, Meerpohl JJ, Morgan RL, Rochwerg B, Darzi A, Rojas MX, Carrasco-Labra A, Adi Y, AlRayees Z, Riva J, Bollig C, Moore A, Yepes-Nunez JJ, Cuello C, Waziry R, Akl EA (2017) GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol 81:101–110. https://doi.org/10.1016/j.jclinepi.2016.09.009 CrossRefPubMed

12.

Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD (2016) GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction. BMJ (Clinical research ed) 353:i2016. https://doi.org/10.1136/bmj.i2016 CrossRef

13.

Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Vandvik PO, Meerpohl J, Guyatt GH, Schunemann HJ (2016) GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines. BMJ (Clinical research ed) 353:i2089. https://doi.org/10.1136/bmj.i2089 CrossRef

14.

Davoli M, Moja L, Amato L, Ferroni E, Tirani M (2015) Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. Recenti Prog Med 106(6):249–280PubMed

15.

Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68(1):1–26

16.

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394. https://doi.org/10.1016/j.jclinepi.2010.04.026 CrossRefPubMed

17.

Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, Johnston BC, Karanicolas P, Akl EA, Vist G, Kunz R, Brozek J, Kupper LL, Martin SL, Meerpohl JJ, Alonso-Coello P, Christensen R, Schunemann HJ (2013) GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 66(2):173–183. https://doi.org/10.1016/j.jclinepi.2012.08.001 CrossRefPubMed

18.

Schünemann HJ, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G, Scholten R, Langendam M, Leeflang MM, Akl EA (2016) GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol 76:89–98CrossRef

19.

Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401–406CrossRef

20.

Guyatt GH, Alonso-Coello P, Schunemann HJ, Djulbegovic B, Nothacker M, Lange S, Murad MH, Akl EA (2016) Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol 80:3–7. https://doi.org/10.1016/j.jclinepi.2016.07.006 CrossRefPubMed

21.

Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post PN, Kunz R (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66(7):719–725CrossRef

22.

Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B (2015) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis: Annrheumdis 2015:207526

23.

Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, Gossec L (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis: Annrheumdis 2013:204588

24.

Menon N, Kothari S, Gogna A, Sharma R (2014) Comparison of intra-articular glucocorticoid injections with DMARDs versus DMARDs alone in rheumatoid arthritis. J Assoc Physicians India 62(8):673–676PubMed

25.

De Cock D, Vanderschueren G, Meyfroidt S, Joly J, Westhovens R, Verschueren P (2014) Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice. Clin Rheumatol 33(1):125–130CrossRef

26.

Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 74(1):27–34CrossRef

27.

Scott DL, Ibrahim F, Farewell V, O’Keeffe AG, Walker D, Kelly C, Birrell F, Chakravarty K, Maddison P, Heslin M (2015) Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ (Clinical research ed) 350:h1046

28.

Heimans L, Wevers-de Boer K, Visser K, Goekoop R, van Oosterhout M, Harbers J, Bijkerk C, Speyer I, de Buck M, de Sonnaville P (2013) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis: Annrheumdis 2013:203243

29.

Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, Bijlsma JW, Burmester GR, Dougados M, Scholte-Voshaar M (2017) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis: Annrheumdis 2016:210713

30.

Zanwar A, Ahmed S, Misra DP, Agarwal V, Sharma A, Wakhlu A, Negi VS (2017) Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Indian J Rheumatol 12(2):104CrossRef

31.

Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73(5):803–809CrossRef

32.

Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B (2016) Non–TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. Jama 316(11):1172–1180CrossRef

33.

Manders SH, Kievit W, Adang E, Brus HL, Moens HJB, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE (2015) Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther 17(1):134CrossRef

34.

Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS (2013) Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res 65(9):1401–1409CrossRef

35.

Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM (2015) Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther 17(1):256CrossRef

36.

Dilla T, Rentero M, Comellas M, Lizan L, Sacristán J (2015) Patients’ preferences for rheumatoid arthritis treatments and their participation in the treatment decision-making process. A systematic review of the literature. Value Health 18(7):A652CrossRef

37.

Huynh TK, Østergaard A, Egsmose C, Madsen OR (2014) Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence 8:93PubMedPubMedCentral

38.

Navarro-Millán I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR (2016) Comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection-related tolerability. PLoS One 11(3):e0149781CrossRef

39.

Nota I, Drossaert CH, Taal E, van de Laar MA (2015) Patients’ considerations in the decision-making process of initiating disease-modifying antirheumatic drugs. Arthritis Care Res 67(7):956–964CrossRef

40.

Poulos C, Hauber AB, González JM, Turpcu A (2014) Patients’ willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res 66(7):1008–1015CrossRef

41.

Harnett J, Wiederkehr D, Gerber R, Gruben D, Koenig A, Bourret J (2016) Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. J Med Econ 19(2):101–112CrossRef

42.

Meissner B, Trivedi D, You M, Rosenblatt L (2014) Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ 17(4):259–265CrossRef

43.

Wailoo A, Hernández Alava M, Scott IC, Ibrahim F, Scott DL (2014) Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology 53(10):1773–1777CrossRef

44.

Zhou Z-Y, Griffith J, Du EX, Chin D, Betts KA, Ganguli A (2016) Economic burden of switching to a non-tumor necrosis factor inhibitor versus a tumor necrosis factor inhibitor biologic therapy among patients with rheumatoid arthritis. Adv Ther 33(5):807–823CrossRef

45.

Montori VM, Brito JP, Murad MH (2013) The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. Jama 310(23):2503–2504. https://doi.org/10.1001/jama.2013.281422 CrossRefPubMed

Medicine Matters Rheumatology

Abstract